Navigation Links
TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Date:5/14/2009

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The current clinical trial is being conducted at six centers in the USA. The study enrolled 28 patients in the dose-escalation phase (completed in February 2009) and 31 patients in the dose-confirmation phase of the study (currently in progress). Primary goals of this open-label study included identification of a maximum tolerated dose (MTD) in the dose-escalation phase and accumulation of safety data, assessments of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints in both phases of the study. Preliminary trial data presented at the 2008 ASH conference indicated that the drug was well tolerated and exhibited dose-dependant reductions of splenomegaly and leukocytosis. Updated clinical data pertaining to this trial are scheduled for presentation at the European Hematology Association (EHA) conference on June 6, 2009 in Berlin.

www.targegen.com

About TargeGen, Inc.

TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors for applications in oncology and inflammatory diseases.


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
4. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
5. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Tris Pharma Announces Acceptance of Its First Two NDAs
8. Bionovo Announces First Quarter 2009 Highlights and Financial Results
9. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
10. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
11. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... focused on delivering scientific and medical breakthroughs using ... and Chief Executive Officer Keith Murphy ... December 14, 2016 at 1:00 p.m. Eastern Time ... yet familiar with the Company, an informational video ...
(Date:12/7/2016)... Today, Stock-Callers.com presents four Biotech equities for review, ... Pharmaceuticals Inc. (NASDAQ: ANTH ), ProNAi Therapeutics Inc. ... AVXS ). From its peak in July 2015, the ... level equal to what it saw at the start of ... year, it has still out-performed other market sectors, beating the ...
(Date:12/7/2016)... 7, 2016  Lannett Company, Inc. (NYSE: LCI ) ... Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 ... New York City . In addition, the ... Guggenheim Securities 4 th Annual Boston Healthcare Conference taking place ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... , ... December 07, 2016 , ... A quote from ... outpouring of comments on social media that offer a rare glimpse into the mind ... ADHD authority and New York Times bestselling author, has described people with ADHD as ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart ... in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is ... for a brain tumor. , Jason Bauer and his family are longtime members ...
(Date:12/7/2016)... ... ... A. Kevin Spann Insurance, a New York-based firm offering insurance and financial consultation ... drive to raise funds that will benefit the Marine Corps League. , The Marine ... Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans to generate ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Delete® - ... in Time For The Holiday Party Season. Save Up To 33% Off Botox® and ... Salon is providing the Phoenix Valley with Delightful Deals on Botox® and ...
(Date:12/7/2016)... ... 2016 , ... Gensuite is honored to be selected as ... Product Launch category. Gensuite’s entry on their EZ Scan feature detailed the tool’s ... Training Group is a professional event and training provider based in the United ...
Breaking Medicine News(10 mins):